Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adefovir vs Tenofovir for Lamivudine-Resistant HBV in HIV Coinfection
NCT00033163Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tenofovir disoproxil fumarate in hepatitis B (HBV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Time-weighted average change from baseline in serum HBV DNA at 48 weeks. Status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00033163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033163.